These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 20967817)

  • 21. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.
    Zmuda F; Malviya G; Blair A; Boyd M; Chalmers AJ; Sutherland A; Pimlott SL
    J Med Chem; 2015 Nov; 58(21):8683-93. PubMed ID: 26469301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
    Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance.
    Michelena J; Lezaja A; Teloni F; Schmid T; Imhof R; Altmeyer M
    Nat Commun; 2018 Jul; 9(1):2678. PubMed ID: 29992957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antimitotic potential of PARP inhibitors, an unexplored therapeutic alternative.
    Iglesias P; Costoya JA
    Curr Top Med Chem; 2014; 14(20):2346-65. PubMed ID: 25434352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.
    Pettitt SJ; Rehman FL; Bajrami I; Brough R; Wallberg F; Kozarewa I; Fenwick K; Assiotis I; Chen L; Campbell J; Lord CJ; Ashworth A
    PLoS One; 2013; 8(4):e61520. PubMed ID: 23634208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
    Lin S; Zhang L; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Chen L; Wu L
    Bioorg Med Chem; 2020 May; 28(9):115434. PubMed ID: 32222339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
    Faraoni I; Compagnone M; Lavorgna S; Angelini DF; Cencioni MT; Piras E; Panetta P; Ottone T; Dolci S; Venditti A; Graziani G; Lo-Coco F
    Biochim Biophys Acta; 2015 Mar; 1852(3):462-72. PubMed ID: 25483710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
    Kwon M; Jang H; Kim EH; Roh JL
    Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
    Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
    EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-Guided Design and In-Cell Target Profiling of a Cell-Active Target Engagement Probe for PARP Inhibitors.
    Howard RT; Hemsley P; Petteruti P; Saunders CN; Molina Bermejo JA; Scott JS; Johannes JW; Tate EW
    ACS Chem Biol; 2020 Feb; 15(2):325-333. PubMed ID: 32017532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region.
    Dallavalle S; Princiotto S; Mattio LM; Artali R; Musso L; Aviñó A; Eritja R; Pisano C; Gargallo R; Mazzini S
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
    McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C
    Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP1 is required for chromosomal translocations.
    Wray J; Williamson EA; Singh SB; Wu Y; Cogle CR; Weinstock DM; Zhang Y; Lee SH; Zhou D; Shao L; Hauer-Jensen M; Pathak R; Klimek V; Nickoloff JA; Hromas R
    Blood; 2013 May; 121(21):4359-65. PubMed ID: 23568489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
    Menear KA; Adcock C; Boulter R; Cockcroft XL; Copsey L; Cranston A; Dillon KJ; Drzewiecki J; Garman S; Gomez S; Javaid H; Kerrigan F; Knights C; Lau A; Loh VM; Matthews IT; Moore S; O'Connor MJ; Smith GC; Martin NM
    J Med Chem; 2008 Oct; 51(20):6581-91. PubMed ID: 18800822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p21CDKN1A Regulates the Binding of Poly(ADP-Ribose) Polymerase-1 to DNA Repair Intermediates.
    Dutto I; Sukhanova M; Tillhon M; Cazzalini O; Stivala LA; Scovassi AI; Lavrik O; Prosperi E
    PLoS One; 2016; 11(1):e0146031. PubMed ID: 26730949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homologous recombination research is heating up and ready for therapy.
    Powell SN; Kachnic LA
    Proc Natl Acad Sci U S A; 2011 Jun; 108(24):9731-2. PubMed ID: 21642535
    [No Abstract]   [Full Text] [Related]  

  • 40. Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors.
    Wang LX; Zhou XB; Xiao ML; Jiang N; Liu F; Zhou WX; Wang XK; Zheng ZB; Li S
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3739-43. PubMed ID: 25086680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.